Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation: 2017-2024

Historic Accumulated Depreciation for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $7.7 million.

  • Crinetics Pharmaceuticals' Accumulated Depreciation rose 53.84% to $9.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $9.6 million, marking a year-over-year increase of 53.84%. This contributed to the annual value of $7.7 million for FY2024, which is 52.57% up from last year.
  • Crinetics Pharmaceuticals' Accumulated Depreciation amounted to $7.7 million in FY2024, which was up 52.57% from $5.1 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Accumulated Depreciation registered a high of $7.7 million during FY2024, and its lowest value of $2.6 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Depreciation was $5.1 million (2023), whereas its average is $5.6 million.
  • Data for Crinetics Pharmaceuticals' Accumulated Depreciation shows a peak YoY spiked of 57.51% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Accumulated Depreciation stood at $2.6 million in 2020, then soared by 36.04% to $3.5 million in 2021, then increased by 17.36% to $4.1 million in 2022, then increased by 24.09% to $5.1 million in 2023, then spiked by 52.57% to $7.7 million in 2024.